EUR 23.6
(1.72%)
Year | Net Income | Net Income Growth |
---|---|---|
2023 | 29.54 Million EUR | 1.48% |
2022 | 29.11 Million EUR | 425.09% |
2021 | -8.95 Million EUR | 87.27% |
2020 | -70.37 Million EUR | -735.41% |
2019 | 11.07 Million EUR | -70.08% |
2018 | 37.02 Million EUR | 16.23% |
2017 | 31.85 Million EUR | -60.21% |
2016 | 80.06 Million EUR | -3.05% |
2015 | 82.58 Million EUR | 1568.5% |
2014 | 4.94 Million EUR | -23.2% |
2013 | 6.44 Million EUR | -56.19% |
2012 | 14.71 Million EUR | 70.23% |
2011 | 8.64 Million EUR | -5.31% |
2010 | 9.12 Million EUR | 79.73% |
2009 | 5.07 Million EUR | 0.0% |
Year | Net Income | Net Income Growth |
---|---|---|
2024 Q2 | 74.52 Million EUR | 0.0% |
2023 FY | 29.54 Million EUR | 1.48% |
2023 Q4 | 44.95 Million EUR | 0.0% |
2023 Q2 | -15.4 Million EUR | 0.0% |
2022 Q4 | 65.1 Million EUR | 0.0% |
2022 FY | 29.11 Million EUR | 425.09% |
2022 Q2 | 4.28 Million EUR | 0.0% |
2021 Q2 | 4.28 Million EUR | 0.0% |
2021 FY | -8.95 Million EUR | 87.27% |
2021 Q4 | 4.28 Million EUR | 0.0% |
2020 Q2 | 4.28 Million EUR | 0.0% |
2020 Q4 | 4.28 Million EUR | 0.0% |
2020 FY | -70.37 Million EUR | -735.41% |
2019 Q2 | -18.23 Million EUR | 0.0% |
2019 FY | 11.07 Million EUR | -70.08% |
2019 Q4 | 4.28 Million EUR | 0.0% |
2018 Q4 | -18.88 Million EUR | 0.0% |
2018 FY | 37.02 Million EUR | 16.23% |
2018 Q2 | 55.9 Million EUR | 0.0% |
2017 Q2 | -2.19 Million EUR | 0.0% |
2017 FY | 31.85 Million EUR | -60.21% |
2017 Q4 | 34.05 Million EUR | 0.0% |
2016 Q4 | 60.45 Million EUR | 0.0% |
2016 FY | 80.06 Million EUR | -3.05% |
2016 Q2 | 19.61 Million EUR | 0.0% |
2015 Q4 | 80.3 Million EUR | 0.0% |
2015 Q2 | 2.28 Million EUR | 0.0% |
2015 FY | 82.58 Million EUR | 1568.5% |
2014 FY | 4.94 Million EUR | -23.2% |
2014 Q2 | 4.54 Million EUR | 0.0% |
2014 Q4 | 400.35 Thousand EUR | 0.0% |
2013 FY | 6.44 Million EUR | -56.19% |
2013 Q4 | 2.21 Million EUR | 0.0% |
2013 Q2 | 4.23 Million EUR | 0.0% |
2012 Q4 | 3.87 Million EUR | 0.0% |
2012 Q2 | 3.48 Million EUR | -0.0% |
2012 Q1 | 3.48 Million EUR | 0.0% |
2012 FY | 14.71 Million EUR | 70.23% |
2012 Q3 | 3.87 Million EUR | 11.19% |
2011 FY | 8.64 Million EUR | -5.31% |
2010 FY | 9.12 Million EUR | 79.73% |
2009 FY | 5.07 Million EUR | 0.0% |
Name | Net Income | Net Income Difference |
---|---|---|
Apontis Pharma AG | -11.3 Million EUR | 361.388% |
Dermapharm Holding SE | 62.36 Million EUR | 52.629% |
Evotec SE | -83.91 Million EUR | 135.209% |
MERCK Kommanditgesellschaft auf Aktien | 2.82 Billion EUR | 98.954% |
PharmaSGP Holding SE | 16.39 Million EUR | -80.182% |
SynBiotic SE | -10.63 Million EUR | 377.92% |